WEDNESDAY, Dec. 1, 2021 (HealthDay News) — With HIV a persistent threat to ladies’ health, the World Health Organization (WHO) has approved the primary lengthy-acting device to shield women from sexually transmitted HIV.
The tool is a vaginal ring made of silicone elastomer, a flexible rubber-like fabric that makes it smooth to insert and comfy to apply. The ring releases the antiretroviral drug dapivirine into the vagina slowly over 28 days.
Two large scientific trials determined it decreased the general risk of HIV-1 infection in women by 35% and 27%, respectively. Similarly, studies suggested a chance reduction of approximately 50%.
The nonprofit International Partnership developed the vaginal ring for Microbicides (IPM). It is the first long-appearing option available to girls to reduce their risk of HIV. It’s anticipated to be had in 2022 in sub-Saharan Africa, wherein ladies urgently need HIV prevention.
“It’s been an extended journey, but we are just thrilled to announce on Worlds AIDS Day that this new ring product will soon be to be had to women to help similarly lessen HIV contamination costs,” said Peter Boyd, from the School of Pharmacy at Queen’s University Belfast, U.K.
He and his colleagues, along with Karl Malcolm, have long been helping improve a new drug-liberating vaginal ring to defend ladies from HIV and are lengthy-time collaborators with IPM.
“The dapivirine ring is simply the beginning. In persisted partnership with IPM, we aim to help in developing different multipurpose merchandise that may offer similarly gain to women’s sexual and reproductive fitness,” Malcom said in a university news release.
The ring changed into lauded via the European Medicines Agency to be used by using women over 18 in growing countries who cannot pick out not to take them every day HIV preventative tablet (PrEP).
WHO’s the approval of the device is for Zimbabwe, and regulatory reviews are ongoing in different international locations in eastern and southern Africa.
According to the WHO, the ring should be blanketed as part of a mixed prevention package for ladies in enormous danger of HIV infection.
Queen’s University Belfast researchers also are running with IPM on a product that provides non-stop release of drugs — dapivirine and levonorgestrel — over three months to protect in opposition to both sexually transmitted HIV infection and unintentional being pregnant.